Skip to content
Search AI Powered

Latest Stories

Chiesi releases additional batches of Clenil Modulite 100mcg

Chiesi has released additional Clenil Modulite 100mcg (beclometasone) batches into the UK supply chain following a steep rise in the demand for the product.

The batches have been released following the Medicines and Healthcare products Regulatory Agency’s (MHRA) authorisation.


The batch numbers authorised by MHRA for release include: 1112190, 1112214, 1112215, 1112217, 1112218, and 1112219.

The first seven batches are expected to be in circulation this week. Further batches will be released over the coming months to address the increase in demand.

“We repeat our appeal to all healthcare professionals involved in prescribing and dispensing our range of products to help us maintain supply by continuing to write monthly repeat prescriptions rather than prescriptions for multiple months’ supply of inhalers until such time as the short-term pressures begin to ease," Chiesi said in a statement.

"This will help us immensely in being able to continue to supply all our products to all our patients during this time by bringing demand in line with supply.”

Key points related to the batch variation

  • These inhalers contain the same active ingredient, beclometasone; no changes are needed to the prescription or the way patients manage their asthma
  • Drug is delivered by the same inhaler device-pressurised metered dose inhaler, pMDI
  • The main changes relate to the product appearance: on the new batches the actuator is beige and the cap is yellow, instead of brown and beige, respectively on the original version
  • There is no dose indicator on the new batches
  • There are no differences to the safety profile (adverse effects) of the drug
  • When dispensing the product, healthcare professionals should carefully check the dosage written on the labelling on the package due to the similarities in colour with Clenil 50mcg inhaler
  • As usual, patients should be recommended to keep track of when they started using the inhaler as there is no dose indicator; at the usual recommended dose the inhaler will last over a month
  • The Clenil inhalers are compatible with a Volumatic Spacer Device
  • Patients should be reminded of the importance of cleaning their inhaler once a week.

More For You

New professional liability insurance policy for RPS members launched

The insurance will be provided to members at cost, with no profit made by RPS.

gettyimages

RPS launches professional liability insurance for members

The Royal Pharmaceutical Society (RPS) has launched a new professional liability insurance policy, designed to empower pharmacists to work confidently and deliver high-quality care, knowing they are protected.

Exclusively available to its members, the comprehensive and affordable insurance has been developed in collaboration with global professional services firm Aon.

Keep ReadingShow less
Scottish community pharmacist working in high street pharmacy with supportive environment

The PDA wants investment to reach those who deliver services to patients every day

Pic credit: iStock

Funding boost in Scotland “needs to work for not just pharmacy owners but pharmacists too”, says PDA

An increase in funding for community pharmacies in Scotland needs to lead to a greater focus on supporting pharmacists rather than “simply sustain business models”, according to the Pharmacy Defence Association (PDA).

Earlier this week, Community Pharmacy Scotland (CPS) accepted the Scottish government’s initial financial offer for the 2025/26 fiscal year, securing a guaranteed minimum reimbursement of £120 million for community pharmacies — up from £110 million from 2024/25.

Keep ReadingShow less
GP surgery upgrades for annual appointments

The surgeries will have additional space to “see more patients, boost productivity and improve patient care”

Pic credit: iStock

GP surgery upgrades to create 8.3 million more annual appointments

Over 1,000 GP surgeries will have their premises modernised to meet the needs of a further 8.3 million appointments each year, the government has announced.

Backed by a cash injection of over £102 million, the surgeries will have additional space to “see more patients, boost productivity and improve patient care”.

Keep ReadingShow less
Wales boosts funding for pharmacy-led UTI and sore throat test services

The sore throat test (STTT) and treat service will be widely available

Pic credit: istock

Welsh pharmacies receive funding boost for clinical services

Two key clinical services will be available in 99 per cent of community pharmacies across Wales after a boost in funding.

The sore throat test (STTT) and treat service and the urinary tract infection (UTI) service have both benefitted from contractual negotiations between the Welsh Government and Community Pharmacy Wales (CPW).

Keep ReadingShow less
Paul Bennett
Paul Bennett, CEO, Royal Pharmaceutical Society
Paul Bennett, CEO, Royal Pharmaceutical Society

Pharmacists need to take advantage of independent prescribing pathways, says Bennett

Independent prescribing will be a “significant point” in the history of community pharmacy, according to Royal Pharmaceutical Society chief executive Paul Bennett.

Last month, the RPS announced the launch of a comprehensive new prescribing development programme to support pharmacists across all stages of their prescribing careers.

Keep ReadingShow less